logo

Calithera Biosciences Inc. (CALA)



Trade CALA now with
  Date
  Headline
10/2/2020 7:14:19 AM Calithera Biosciences Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
9/24/2020 7:28:12 AM Calithera Begins KEAPSAKE Randomized Phase 2 Trial Of Telaglenastat Plus Chemoimmunotherapy
8/3/2020 7:16:21 AM Calithera Reports New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
7/13/2020 7:10:50 AM Calithera Biosciences Begins Phase 1b Trial Of Arginase Inhibitor CB-280
7/2/2020 7:15:06 AM Calithera Biosciences Announces New Employment Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
6/2/2020 7:11:16 AM Calithera Biosciences Announces New Employment Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
4/16/2020 12:38:55 AM Calithera Biosciences Prices Public Offering Of 5 Mln Shares At $6.25/Shr
1/13/2020 7:54:51 AM Calithera Expects To Utilize Cash And Investments $75 Mln-$85 Mln In 2020
1/3/2020 7:28:45 AM Calithera Biosciences Reports New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
12/6/2019 7:07:51 AM Calithera Biosciences To Present Data From Phase 2 Study Of Telaglenastat With Azacitidine
7/2/2019 8:20:12 AM Calithera Biosciences Begins Phase 1/2 Trial Of Telaglenastat In Combination With Pfizer’s CDK4/6 Inhibitor Palbociclib
6/17/2019 6:11:47 AM Calithera Biosciences Reports Positive Results From Randomized Phase 2 ENTRATA Study Of Telaglenastat With Everolimus
3/26/2019 7:11:38 AM Calithera Biosciences Initiates Phase 1/2 Trial Of Telaglenastat In Combination With PARP Inhibitor Talazoparib
2/4/2019 7:07:37 AM Calithera Biosciences Completes Patient Enrollment In Randomized Phase 2 ENTRATA Trial Of Telaglenastat And Everolimus
1/7/2019 7:21:30 AM Calithera Provides Corporate Updates, Incl Q4 Financial Results, Financial Guidance And Corporate Milestones For 2019
6/4/2018 8:18:11 AM Calithera Biosciences Announces Clinical Data From Lead Product Candidate CB-839